Luca Benatti
Chief Executive Officer
Pharmaceutical Sciences
EryDel SpA
Italy
Biography
Dr Luca Benatti is the Chief Executive Officer since June 2012. He has over 25 year experience in Pharma and Biotech. He was Co-founder, CEO and Member of the Board of Newron Pharmaceuticals. Under his guidance, Newron developed a pipeline of innovative therapies, with most advanced compound Xadago recently approved for the treatment of Parkinson's disease. He is an independent Board member at Newron (Swiss Stock Exchange), Intercept Pharmaceuticals (Nasdaq), Vice President of the Italian Association for Biotechnology and Chairman of Italian Angels for Biotech. Luca graduated and performed his post-doctoral training at Milano Genetics Institute. He has authored several scientific publications and holds numerous patents.
Research Interest
Pharmacology
